Natalizumab Therapy for Moderate to Severe Crohn Disease in Adolescents

ABSTRACT Objectives: This study evaluated the safety, tolerability, and efficacy of natalizumab, a humanized monoclonal immunoglobulin‐G4 antibody to α4 integrin, in adolescent patients with moderately to severely active Crohn disease (CD). Patients and Methods: In a single‐arm study, 38 adolescent...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of pediatric gastroenterology and nutrition 2007-02, Vol.44 (2), p.185-191
Hauptverfasser:	Hyams, Jeffrey S, Wilson, David C, Thomas, Adrian, Heuschkel, Robert, Mitton, Sally, Mitchell, Brent, Daniels, Regina, Libonati, Michele A, Zanker, Susan, Kugathasan, Subra
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adolescents Antibodies, Monoclonal - immunology Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Biological and medical sciences Child Crohn disease Crohn Disease - drug therapy Crohn Disease - immunology Female Gastroenterology. Liver. Pancreas. Abdomen Humans Immunomodulators Immunosuppressive Agents - immunology Immunosuppressive Agents - pharmacology Immunosuppressive Agents - therapeutic use Integrin alpha4 - immunology Male Medical sciences Natalizumab Other diseases. Semiology Pharmacology. Drug treatments Quality of Life Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!